Rice Hall James & Associates LLC Sells 48,566 Shares of Supernus Pharmaceuticals, Inc. $SUPN

Rice Hall James & Associates LLC reduced its stake in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) by 9.3% in the 3rd quarter, Holdings Channel reports. The firm owned 476,081 shares of the specialty pharmaceutical company’s stock after selling 48,566 shares during the quarter. Supernus Pharmaceuticals accounts for 1.2% of Rice Hall James & Associates LLC’s investment portfolio, making the stock its 22nd largest holding. Rice Hall James & Associates LLC’s holdings in Supernus Pharmaceuticals were worth $22,752,000 at the end of the most recent reporting period.

Other institutional investors have also recently made changes to their positions in the company. Quantbot Technologies LP bought a new position in shares of Supernus Pharmaceuticals during the first quarter worth about $103,000. AlphaQuest LLC boosted its holdings in Supernus Pharmaceuticals by 26.1% in the first quarter. AlphaQuest LLC now owns 4,868 shares of the specialty pharmaceutical company’s stock valued at $159,000 after acquiring an additional 1,008 shares during the last quarter. Trexquant Investment LP increased its position in Supernus Pharmaceuticals by 94.5% during the 1st quarter. Trexquant Investment LP now owns 144,494 shares of the specialty pharmaceutical company’s stock valued at $4,732,000 after purchasing an additional 70,219 shares during the period. State of Wyoming raised its holdings in Supernus Pharmaceuticals by 58.8% during the 1st quarter. State of Wyoming now owns 4,754 shares of the specialty pharmaceutical company’s stock worth $156,000 after purchasing an additional 1,761 shares during the last quarter. Finally, Vident Advisory LLC lifted its position in shares of Supernus Pharmaceuticals by 3.4% in the 1st quarter. Vident Advisory LLC now owns 14,886 shares of the specialty pharmaceutical company’s stock worth $488,000 after purchasing an additional 494 shares during the period.

Wall Street Analyst Weigh In

A number of brokerages recently weighed in on SUPN. Zacks Research downgraded shares of Supernus Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Monday, December 8th. Stifel Nicolaus lifted their price objective on Supernus Pharmaceuticals from $50.00 to $55.00 and gave the stock a “hold” rating in a research report on Friday, December 19th. Piper Sandler raised Supernus Pharmaceuticals from a “neutral” rating to an “overweight” rating and boosted their price objective for the company from $40.00 to $65.00 in a research note on Thursday, October 9th. Cantor Fitzgerald raised their target price on Supernus Pharmaceuticals from $46.00 to $63.00 and gave the stock an “overweight” rating in a research note on Tuesday, September 30th. Finally, Weiss Ratings reiterated a “sell (d+)” rating on shares of Supernus Pharmaceuticals in a report on Monday. Four investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Supernus Pharmaceuticals has a consensus rating of “Hold” and an average price target of $61.60.

Insider Buying and Selling at Supernus Pharmaceuticals

In other Supernus Pharmaceuticals news, CEO Jack A. Khattar sold 59,900 shares of the company’s stock in a transaction on Thursday, October 9th. The shares were sold at an average price of $50.57, for a total transaction of $3,029,143.00. Following the transaction, the chief executive officer owned 1,206,578 shares in the company, valued at approximately $61,016,649.46. This represents a 4.73% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, VP Padmanabh P. Bhatt sold 710 shares of Supernus Pharmaceuticals stock in a transaction dated Thursday, December 18th. The shares were sold at an average price of $44.44, for a total transaction of $31,552.40. Following the transaction, the vice president owned 14,508 shares of the company’s stock, valued at $644,735.52. This represents a 4.67% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last 90 days, insiders sold 90,845 shares of company stock worth $4,560,380. 8.80% of the stock is owned by corporate insiders.

Supernus Pharmaceuticals Price Performance

Shares of SUPN opened at $51.57 on Friday. The stock has a 50-day moving average of $48.50 and a 200-day moving average of $43.03. Supernus Pharmaceuticals, Inc. has a one year low of $29.16 and a one year high of $57.65. The company has a market cap of $2.96 billion, a PE ratio of -151.67, a P/E/G ratio of 0.62 and a beta of 0.71.

Supernus Pharmaceuticals (NASDAQ:SUPN) last announced its quarterly earnings data on Tuesday, November 4th. The specialty pharmaceutical company reported $0.46 EPS for the quarter, missing analysts’ consensus estimates of $0.82 by ($0.36). Supernus Pharmaceuticals had a negative net margin of 2.81% and a positive return on equity of 11.51%. The firm had revenue of $170.00 million during the quarter, compared to analyst estimates of $175.82 million. During the same period last year, the business posted $0.69 EPS. The company’s revenue was up 9.3% on a year-over-year basis. Analysts expect that Supernus Pharmaceuticals, Inc. will post 2.38 EPS for the current fiscal year.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, headquartered in Rockville, Maryland, is a specialty pharmaceutical company dedicated to developing and commercializing central nervous system (CNS) therapies. Since its founding in 2003, Supernus has focused on advancing treatments for neurological disorders, with an emphasis on improving patient quality of life through innovative dosage forms and sustained‐release formulations.

The company’s marketed portfolio includes Trokendi XR and Oxtellar XR, extended‐release antiepileptic medications designed to maintain stable drug levels for seizure control, as well as Qelbree (viloxazine extended‐release capsules), approved for the treatment of attention‐deficit/hyperactivity disorder (ADHD) in pediatric and adult patients.